Abstract:KEYWORDS: Psoriasis is a chronic inflammatory disease of the skin, associated with systemic inflammation leading to the concept of 'psoriatic march' or 'inflammatory skin march.' In particular, psoriasis is associated with an increased risk of developing severe vascular events such as myocardial infarction and stroke; the prevalence of cardiovascular (CV) risk factors such as hypertension, diabetes mellitus, dyslipidemia, obesity, subclinical atherosclerosis and smoking is increased. Consequently, mortality rates have been found to be increased in patients with psoriasis, mainly due to CV comorbidities, with a life expectancy decreased by approximately 5 years in moderate to severe cases [ Citation 1 ]. CV disease (CVD) constitutes the first cause of mortality among psoriasis patients, with a higher risk among severe patients (psoriatic patients have a risk for myocardial infarction 2.4 times higher than general population, and a 48% and 38% higher risk for stroke and CV mortality, respectively). Duration of psoriasis has also been associated with CVD risk [ Citation 2 , Citation 3 ].

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the effectiveness of biotherapies in reducing psoriasis - related cardiovascular risks. Specifically, the paper explores the clinical and pathophysiological associations between psoriasis and cardiovascular diseases, and evaluates the effects of different types of biotherapies (such as TNFα inhibitors, IL17 inhibitors, IL12/IL23 inhibitors, etc.) in reducing cardiovascular risks. ### Overview of the main problems: 1. **The relationship between psoriasis and cardiovascular diseases**: - Psoriasis is a chronic inflammatory disease, related to systemic inflammation, leading to the concepts of "psoriasis progression" or "inflammatory skin progression". - Patients with psoriasis have an increased risk of cardiovascular events (such as myocardial infarction and stroke). - Cardiovascular risk factors (such as hypertension, diabetes, dyslipidemia, obesity, subclinical atherosclerosis, and smoking) are more common in patients with psoriasis. - Cardiovascular diseases are the main cause of death in patients with psoriasis, especially in severe cases, and the life expectancy of patients is shortened by about 5 years. 2. **The effects of biotherapies**: - Biotherapy is a first - line treatment option for patients with moderate - to - severe psoriasis. - Currently approved biotherapies include TNFα inhibitors (such as adalimumab, certolizumab pegol, etanercept, infliximab), IL17 inhibitors (such as bimekizumab, brodalumab, ixekizumab, secukinumab), IL12/IL23 inhibitors (such as ustekinumab), IL23 inhibitors (such as guselkumab, risankizumab, tildrakizumab). - The paper evaluates the effects of these biotherapies in reducing cardiovascular inflammatory markers, improving endothelial function, and reducing coronary artery plaques. ### Specific research contents: - **TNFα inhibitors**: These drugs can reduce inflammation markers related to endothelial dysfunction, such as C - reactive protein and vascular endothelial growth factor, as well as cardiovascular inflammation markers, such as glycoprotein acetylation (GlycA), IL6, and TNFα. - **IL17 inhibitors**: These drugs can reduce the level of peripheral oxidative stress, vascular inflammation, and pro - inflammatory cytokines, and at the same time, the effect on reducing coronary artery plaque markers is better than that of TNFα and IL12/IL23 inhibitors. - **IL12/IL23 inhibitors**: These drugs can significantly reduce the levels of proteins related to cardiovascular risks, especially IL6, MPO, CXCL10, E - selectin, von Willebrand factor, etc. ### Conclusions: - Evaluating cardiovascular risks should become a routine practice in the clinical management of patients with psoriasis. - Treatment decisions should be individualized, and patients should work closely with healthcare providers to evaluate the potential benefits and risks of biotherapies. - For patients with high cardiovascular risks, special examinations may be required, while patients with low - to - moderate risks can benefit from risk - reduction treatments. Through these studies, the paper aims to provide scientific basis and clinical guidance for cardiovascular risk management in patients with psoriasis.

Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk

Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities

Association between the systemic treatment of psoriasis and cardiovascular risk

Psoriasis a Cause of Cardiovascular Diseases: A Review Article

Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review

Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities

Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies

Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review

Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease

The concept of psoriasis as a systemic inflammation: implications for disease management

FUNCTIONAL STATE OF ENDOTHELIUM IN PATIENTS WITH PSORIASIS

Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome

Arterial function is preserved in successfully treated patients with psoriasis vulgaris

Cardiovascular comorbidity in psoriasis – psoriatic inflammation is more than just skin deep

Early Cerebral Microvasculature Impairment and Increased Body Mass Index in Patients with Psoriasis

Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study

Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function

Cardiovascular comorbidities in psoriatic arthritis: state of the art

Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers

Assessing the Association between Psoriasis and Cardiovascular Ischemia: An Investigation of Vascular Endothelial Growth Factor, Cutaneous Angiogenesis, and Arterial Stiffness

The cardiometabolic conditions of psoriatic disease